Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Patent
1994-10-07
1996-09-24
Springer, David B.
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
A61K 31405, A61K 3140
Patent
active
055591434
ABSTRACT:
The present invention is directed to a new class of serotonin 5HT.sub.1A agonists.
REFERENCES:
patent: 2725386 (1955-11-01), Bovei et al.
patent: 4614807 (1986-09-01), Flaugh et al.
Marinus O. den Boer, et al, Br. J. Pharmacol (1991), 102, pp. 323-330, Role of 5HT.sub.1 -like receptors in the reduction of porcine cranial arteriovenous anastomotic shunting by sumatriptan.
Saxena, et al, TIPS, May 1989, vol. 10, pp. 200-204; 5HT.sub.1 -like receptor agonists and the pathophysiology of migraine.
Hamel et al., Br. J. Pharmacol, (1991), 102, pp. 227-233; Contractile 5HT.sub.1 receptors in human isolated pial arterioles: correlation with 5-HT.sub.1D binding sites.
Edward E. Schweizer, et al.; Psychopharmacology Bulletin, vol. 22, No. 1, 1986, pp. 183-185; Open Trial of Buspirone in the Treatment of Major Depressive Disorder.
European Journal of Pharmacology, 180 (1990) pp. 339-349, Dreteler, et al.; Comparision of the cardiovascular effects of the 5-HT1A receptor agonist flexinoxan with that of 8-OH-DPAT in the rat.
European Journal of Pharmacology, 182 (1990) 63-72, Connor, et al.; Cardiovascular effects of 5HT.sub.1a receptor agonists injected into the dorsal raphe nucleus of conscious rats.
European Journal of Pharmacology, 163, (1989) 133-136, Peroutka, et al; Sumatriptan (GR 43175) interacts selectively with 5-HT.sub.1B and 5-HT.sub.1D binding sites.
Bernotas Ronald C.
Dudley Mark W.
McDonald Ian A.
Sprouse Jeffrey S.
Dixon J. Michael
Merrell Pharmaceuticals Inc.
Springer David B.
LandOfFree
Serotonin 5HT.sub.1A agonistic method does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Serotonin 5HT.sub.1A agonistic method, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Serotonin 5HT.sub.1A agonistic method will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-1928729